I consent to receiving electronic communication to the above e-mail address from MEDAPP S.A. with registered office in Kraków, 30-150 Kraków, ul. Armii Krajowej 25, NIP [tax ID]: 7010264750, REGON [company register ID]: 142641690, with KRS [National Court Register] number 00000365157, whose registration documents are held by the District Court for Kraków-Śródmieście in Kraków, 11th Economic Division of the National Court Register, in order to receive the MEDAPP S.A. Newsletter.
I consent to receiving commercial information concerning MEDAPP S.A. products and services from MEDAPP S.A. with registered office in Kraków, 30-150 Kraków, ul. Armii Krajowej 25, NIP [tax ID]: 7010264750, REGON [company register ID]: 142641690, with KRS [National Court Register] number 00000365157, whose registration documents are held by the District Court for Kraków-Śródmieście in Kraków, 11th Economic Division of the National Court Register, to the e-mail address provided above.
I certify that I have read and understand the Privacy Policy.
You may withdraw your consent at any time by contacting us at iodo@medapp.pl. Your telecommunications terminal equipment (e.g. telephone/computer) and automated calling systems within the meaning of the Telecommunications Law (i.e. Journal of Laws 2021, item 576 as amended) will be used for sending commercial information.
MedApp with record FY 2021 results, doubling revenue and profits from previous year
MedApp reported PLN 12.7 million in net sales revenue cumulatively after four quarters of 2021, 111% higher than a year earlier. EBITDA increased by 139% to PLN 6.3 million, and net profit was twice higher year-on-year, reaching PLN 3.8 million. The company also boasts high profitability.
The tech company MedApp applies to list 209 million shares
“Due to the high volatility of the capital market, we have temporarily suspended the prospectus procedure, but at the same time we want to introduce not yet admitted shares to trading on NewConnect,” says Krzysztof Mędrala, CEO of MedApp S.A.
